Oscotec Inc.

Translating science into medicine
Sign Up
PRESS
  1. No Image 01Jun
    by

    "ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"

  2. No Image 01Jun
    by

    "Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"

  3. No Image 01Jun
    by

    Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models

  4. No Image 01Jun
    by

    AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

  5. No Image 01Jun
    by

    G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.

  6. No Image 01Jun
    by

    Genosco gears up for IPO

  7. No Image 01Jun
    by

    Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

  8. No Image 01Jun
    by

    INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs

  9. No Image 01Jun
    by

    IPOs spawn instant billionaires

  10. No Image 01Jun
    by

    Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

  11. No Image 01Jun
    by

    Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech

  12. No Image 01Jun
    by

    Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.